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Parkinson’s disease (PD) is a degenerative neurological disease presenting with motor and non-motor
signs and symptoms. Approximately 30e50% of the patients experience pain. There is no consensus
regarding the mechanisms and classiﬁcation of pain in PD. This paper reviews current data on the
possible mechanisms, classiﬁcations, evaluation and potential risk factors for pain in PD. Literature
searches were performed to identify clinical trials and reviews covering patho-physiology, classiﬁcation,
type, evaluation and risk factors associated with pain in PD. Pain in PD could be related to pathologic
changes in the anatomic structures involved in nociceptive mechanisms. Studies on pain mechanisms
have been mostly conducted in animals. The mechanism of pain is complicated and inﬂuenced by
different factors. There are several methodological differences between the studies trying to classify pain
and to characterize its subtypes. Potential risk factors for pain in PD include: age, gender, and duration of
the disease. Although pain is one of the non-motor symptoms most frequency experienced by patients, it
is often under recognized and inadequately treated in contrast to motor symptoms Multicenter studies
are needed that include a large cohort of subjects evaluated in multiple dimensions including pain in
order to obtain more data and to allow improved management of pain in patients with PD.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Parkinson’s disease (PD) is a chronic, progressive neurodegen-
erative disease characterized by loss of nigrostriatal dopaminergicSalud, Universidad Rey Juan Carlo
dez@urjc.es (C. Fernández-de-las-
-ND license.pathways [1]. Its prevalence in the general population is 0.1e0.3%
[2], showing an increase in individuals aged  65 years [3].
Cardinal ﬁndings in PD are tremor, rigidity, akinesia (i.e., bradyki-
nesia, hypokinesia) and postural instability. In addition to motors, Avenida de Atenas s/n, 28922 Alcorcón, Madrid, Spain. Tel.: þ34 91 488 88 84;
Peñas).
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these patients. These symptoms are classiﬁed as autonomic, i.e.,
hyperhidrosis, orthostatic hypotension, sexual-urinary dysfunction,
thermoregulation changes, cardiovascular disturbances, peripheral
edema, dilated pupillae), sleep disturbances, neuropsychiatric
problems, i.e., apathy, fatigue, anhedonia, depression, anxiety,
panic attacks, dementia, psychosis, and sensory, i.e., internal
tremor, restless leg syndrome, numbness, paresthesia, visual
disturbances, and pain [4e7]. Among these sensory symptoms,
pain is observed in approximately 30e50% of PD patients; however,
the incidence can increase to 68e85% when all types of pain are
taken into account [8]. Pain can appear at any time during the
disease, and can be present before diagnosis [9]. There is no
consensus on the classiﬁcation and the mechanisms of pain in PD
patients. The objective of this review is to review the available data
on the possible mechanisms, classiﬁcation, evaluation and poten-
tial risk factors for pain in individuals with PD.
2. Methods
2.1. Data sources
We performed computerized English language literature searches to identify
clinical and controlled trials and reviews of pain in patients with PD making use of
the following databases: PubMed (from 1975), Ovid MEDLINE (from 1975), Ovid
EMBASE (from 1975), Cochrane Database of Systematic Reviews (CDSR), Cochrane
Collaboration Trials Register (CCTR), Cumulative Index to Nursing and Allied Health
Literature (CINAHL) and PEDro (Physiotherapy Evidence Database).
We used the following Medical Subject Headings (MeSH) and main key words
for searches: classiﬁcation, patho-physiology, assessment, risk factors, Parkinson
disease or pain. The search was supervised by a librarian scientist who helped us
during each stage of the search. When database facilities allowed search limits,
searches were restricted to clinical or controlled trials. We also reviewed the
reference lists of the papers that we identiﬁed during the searches. Two authors
independently reviewed the selected articles. Published proceedings and abstracts
were excluded.
2.2. Data-extraction
As with article selection, data from each study were extracted independently by
2 authors. A standardized data-extraction form containing questions on population,
methodology, results, and outcome measures was used according to the Consoli-
dated Standards of Reporting Trials (CONSORT) statement. For each selected article,
the following data were recorded: inclusioneexclusion criteria, design, description
of study subject attrition and subject/investigator blinding, outcome measures, and
results. Finally, both authors had to achieve a consensus on each item on the data-
extraction form. In case of no consensus, a third author helps in the decision.
3. Results
3.1. Patho-physiology of pain and Parkinson’s disease
In 1986, painwas deﬁned as a sensory and emotional experience
associated with real or potential injuries or described in terms of
such injuries, by the International Association for the Study of Pain
(IASP) [10]. It is known that several anatomic structures are
involved at the same time in nociception. The process leading to
pain starts with the stimulation of nociceptors. The thinly myelin-
ated Ad nociceptors response to mechanical and thermal stimuli,
while the un-myelinated C-ﬁber nociceptors (polymodal) usually
respond to mechanical, thermal, or chemical stimulation. The
stimuli from nociceptors arrive to the dorsal horn neurons of the
spinal cord. The lamina II, also known as substantia gelatinosa, plays
a major role in pain modulation at the spinal cord [10,11]. This area
forms an intermediate system regulating the transmission to the t-
cells on the lamina V, which in turn mediates the transmission of
sensory stimuli to the brain. The substantia gelatinosa system acts as
an inhibitory mechanism on the t-cells. Stimulation of the Ad and C
ﬁbers inhibits the substantia gelatinosa cells, reducing the output
and their inhibitory action on the t-cells. As a result, the t-cellsincrease their activity. The result is a reduction in the capacity of t-
cells to receive the stimuli or react to them. This is, essentially, the
gate-theory mechanism at the spinal level [12].
Two phylogenetically distinct systems, the medial and lateral
pain systems, transmit pain to higher center brain neurons. The
medial system is mainly constituted of paleospinothalamic, spi-
nomesencephalic, spinoreticular, spinoparabrachial hypothalamic
and spinothalamic tract ﬁbers. These ﬁbers travel in a caudal and
rostral direction to higher centers by terminating in the para-
brachial nucleus, the locus cæruleus (reticular formation), the peri-
aqueductal gray substance (mesencephalon), intra-laminar and
medial thalamic nuclei, thalamic ventral caudal parvocellular
nucleus and ventral caudal portae, the insula, parietal operculum,
the secondary somatosensory cortex, the amygdale and hippo-
campus (Fig. 1). The medial system is involved in the affective and
cognitive-evaluative dimension of pain, pain memory, and auto-
nomic responses. Similarly, the lateral system is formed by the
neospinothalamic, the neotrigeminothalamic, and the cervical
bundle and the beam of the dorsal horn. In the higher centers, these
ﬁbers terminate in the lateral thalamus, the primary and secondary
somatosensory areas, the parietal operculum and the insula (Fig. 1).
The lateral system is important for the sensory-discriminative
component of pain since it provides information about pain local-
ization and duration [10,11,13,14].
The descending pathways originating in the brain stem and
cerebral structures also play an important role in the integration
and modulation of nociceptive information in the dorsal horn. The
serotonergic, noradrenergic and dopaminergic networks are the
principal components of these descending pain mechanisms. The
sensitivity of the dorsal horn neurons can be increased or decreased
by these pathways [11].
PD, as a multifocal degenerative and progressive disease, could
affect the pain process at multiple levels, from the transmission of
the pain from peripheral structures to the higher centers, to its
reception and interpretation as well as interfering with several
anatomic structures involved in pain mechanism. In a study with
PD patients, Nolano et al. showed that signiﬁcant losses occur at the
level of free nerve endings and encapsulated nerve endings (i.e.,
Meissner’s corpuscles), independently of age or disease duration
[15]. They indicated that these changes in receptor size and
peripheral deafferentation could play a relevant role in the patho-
genesis of the sensory dysfunction of PD [15]. Starting in early stage
PD, degenerative changes can also occur in the spinal cord. Certain
neuronal losses have been observed in Lamina I of the posterior
spinal horn [16].
Braak et al. divided the disease into 6 periods [17,18]. The
changes typical of the pre-motor period start in the olfactory bulb
and progress toward the inferior brain stem area (including the
medulla oblongata and pontine tegmentum) of Lewy neurites and
Lewy bodies (period 1e2). In the following symptomatic periods,
pathologic changes take place in the mid brain including the sub-
stantia nigra (period 3), the meso-cortex (period 4), and ﬁnally the
neo-cortex (periods 5e6) [17,18]. Nociceptive information cannot
be transmitted directly from the spinal cord to higher centers
[19,20], since it is modulated by the descending pathways involving
various brain stem nuclei. Some of these nuclei are affected early in
PD [21]. As a result, this classiﬁcation into 6 periods can be helpful
for understanding those changes taking place in the anatomical
structures of the pain related higher centers during the course
of PD.
When examining the brain stem in PD, it is observed that ros-
tromedial medulla, comprising the nucleus raphe magnus and
gigantocellular reticular nucleus, starts to be affected in period 2 of
PD. This area is important for its role in the descending regulation
of pain since it is the last station of the descending anti-nociceptive
Fig. 1. Central pain pathways in Parkinson’s disease. Left: The lateral system is formed by the neospinothalamic, the neotrigeminothalamic, the cervical bundle and the beam of the
dorsal horn which ﬁbers terminate in the lateral thalamus, the primary and secondary somatosensory areas, the parietal operculum and the insula. Right: The medial system is
mainly constituted by the paleospinothalamic, spinomesencephalic, spinoreticular, spinoparabrachial hypothalamic and spinothalamic tract ﬁbers which terminate in the para-
brachial nucleus, the locus cæruleus, the peri-aqueductal gray substance, intra-laminar and medial thalamic nuclei, thalamic ventral caudal parvocellular nucleus and ventral caudal
portae, the insula, parietal operculum, the secondary somatosensory cortex, the amygdale and hippocampus.
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tive modulation within the thalamus [24]. Consequently, the
presence of Lewy bodies in the coeruleus/sub-coeruleus area,
which also plays a role in the noradrenergic modulation of pain, as
well as in intra-laminar and medial thalamic nuclei, could have an
effect on autonomous, motivational-emotional and cognitive-
evaluative responses [13e25]. Serotonergic input to the spinal
dorsal horn from the caudal raphe affects the mechanisms of pain
by facilitating the nociceptive transmission of the mechanical
stimuli, and through such facilitation repressing the ﬁrst reaction to
neurologic inﬂammation and to the chemical activation of primary
afferents [26]. The caudal raphe nuclei and the nucleus raphe
magnus, which are reciprocally linked [27], together with the
coeruleus/sub-coeruleus area, make up the functional gain-setting
system. This system transforms important inputs from the higher-
level components of the limbic lobe into descending projections by
controlling the excitability of the spinal and medullary pre-motor
and motor neurons of the somato-motor system [28,29].
Together with the locus coeruleus, the gigantocellular nucleus
and the nuclei of the bulbar raphe, the peri-aqueductal gray matter
and the parabrachial nuclei play an important role in the modula-
tion of spinal nociceptive transmission, e.g., on inhibition of noci-
ceptive stimuli coming from the dorsal horn neuron. A disturbance
in this pain-inhibiting region could cause an increase in the
sensation of pain [13].
The lateral thalamus, one of the higher centers important for
pain mechanisms, also plays a major role in central pain. Dener-
vation of the nigrostriatal system increases neuronal activity in thesubthalamic nucleus, the internal globus pallidus, and the sub-
stantia nigra pars reticulata. Hyperactivity in these areas leads to
a strong inhibition of the lateral thalamic region, which can affect
pain mechanisms in two different ways: 1), disinhibition of medial
spinothalamic-cortical pathways to the anterior cingulate cortex
due to the disruption of the lateral spinothalamic-cortical pathway
to the parietoinsular system [30]; 2), inhibition of the lateral thal-
amus reducing localization, one of the sensory discrimination
elements of pain. The difﬁculty that patients have in localizing their
pain symptoms supports this hypothesis. On the other hand, other
properties of sensory discrimination become more sensitive to
sensory stimuli [13]. This may explain the changes in pressure and
thermal pain thresholds observed in PD.
Animal studies analyzing the effects of basal ganglia and
dopamine on sensory pathways and their contribution to sensory
perception reﬂect the importance of this region for pain [19].
The neurons within the substantia nigra are responsive to low-
intensity deep mechanical stimuli (e.g. brushing, tapping, pressure)
and electrical stimuli which decrease or increase the discharge ratio
as compared to resting discharge. The nigral neuron responses can
depend on behavioral situations including the application of low-
intensity stimuli. As with non-nociceptive nigral neurons, noci-
ceptive neurons within the substantia nigra may respond with
suppression or enhancement of discharge frequency following
noxious stimulation and have large receptive ﬁelds that often
include thewhole body. The large receptiveﬁelds of nociceptive nigral
neurons show that these neurons have no major effect on the spatial
localization of painful stimuli [19]. Some studies, however, have
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noxious stimuli [31], indicating that certainnociceptivenigralneurons
may play a relevant role in sensory discrimination [19]. Animal
experimentshaveshownthat stimulating the substantianigra leads to
nociceptive inhibition by activating the spinal cord neurons through
dopaminergicpathways [32e35].Basedon theresultsof thesestudies,
it could be postulated that involvement of the substantia nigra in
patients with PD affects the discriminatory aspect of pain and
behavioralpain responses. Inaddition, striatal neurons that respond to
low-threshold somatosensory stimulation also have large cutaneous
receptive ﬁelds [36] and can play a role in the localization of and the
response to stimuli from circumscribed regions [37e39].
Multi-sensory inputswithin the striatum lead to the view that this
area plays a role in the coordination of behavioral responses by
integrating sensory information conveyed by different sensory
methods. The wide dynamic range of neurons, which exhibit low
mechanical thresholds, are sensitive to somatosensory stimuli across
a broad range of stimulus intensities and aremaximally responsive to
noxious stimuli as well, some nociceptive neurons within the stria-
tum could be coding for the intensity of noxious stimuli. The ability of
striatal neurons to receive nociceptive stimuli from a large receptive
area might indicate that these structures do not play a role in the
spatial localization of painful stimuli; the striatummay, however, act
in concertwith somatotopically organized areas that are co-activated
and provide precise spatial information for the next level of integra-
tion [19]. Dopamine secretion during painful stimuli has been iden-
tiﬁedwithin thedorso-lateral striatum.This typeof responsedepends
on the subjective perception of pain intensity. Additionally, the
ventral striatum is clearly related to the emotional dimension of the
human pain process and expectation [40]. In conclusion, striatum
involvement in PD could affect the emotional dimension of pain and
the subjective perception of pain intensity.
Dopamine may also modulate pain at different levels including
the spinal cord, thalamus, peri-aqueductal gray matter, the basal
ganglia and the cingulate gyrus [41]. Axons coming from key
dopaminergic areas, such as the substantia nigra pars compacta,
the ventral tegmental area and the hypothalamus project to mes-
ocortical, mesolimbic, nigrostriatal and tuberoinfundibular path-
ways. These pathwaysmediate different non-motor symptoms, e.g.,
cognition, sleep and pain [41]. Mendlin observed that serotoninwas
not secreted after blocking postsynaptic D2 receptors in rats [42].
Serotonin secretion in the forebrain is dependent on intact local
dopaminergic neurotransmission, as serotonin has an important
role in the sensory and emotional properties of pain. A lesion of the
striatum dopamine terminals can also modify pain transmission
[43]. A signiﬁcant reduction of the nociceptive delay and an
acceleration of the initial and ﬁnal periods of nociceptive stimula-
tion have been observed with lesions of this area. This condition
effectively increases the nociceptive stimuli [44]. Finally, in a posi-
tron emission tomography (PET) study conducted by Brefel-
Courbon et al. increased brain activity during “off” periods was
observed in the right insular, right prefrontal and left anterior
cingulate cortex when subjects were exposed to experimental pain
[20]. It was suggested that levodopa could reverse these results. In
several pain studies, changes in threshold were observed after the
administration of levodopa [20,45,46]. These results reveal the
importance of dopamine in pain transmission.
3.2. Classiﬁcation and types of pain in Parkinson’s disease (PD)
Pain in PD manifests in different parts of the body and different
types of pain has been described. As a result, no consensus has been
reached on the classiﬁcation of pain in PD. Classiﬁcation generally
follows the etiology of the pain [8,47e54]. Snider et al. distin-
guished two main groups of sensory and pain symptoms: primary(i.e. originating in the nervous system) and secondary (other
sources than the nervous system, e.g., the musculoskeletal) [47]. As
new knowledge has emerged regarding themechanisms, frequency
and other properties of pain, more comprehensive classiﬁcations
have been proposed (Table 1). Ford’s classiﬁcation is the most
commonly used [55]. Ford [55] and Goetz et al. [48] distinguish the
following categories: musculoskeletal pain, radicular/neuropathic
pain, dystonia-related pain, akathitic discomfort/pain and central
parkinsonian pain [48,55]. Finally, classiﬁcations that correlate the
pain, directly or indirectly, with the disease have recently been
proposed [48,55].
Musculoskeletal pain covers pain arising from muscular, joint
and postural etiologies, includingmuscle cramps. Muscle cramps or
tightness in patients with PD can affect any part of the body but it
appears more typically in the neck, arm, paraspinal or calf muscles;
while joint pain occurs most frequently in shoulder, hip, knee, and
ankle. The prevalence of musculoskeletal pain ranges from 45% to
74% in those patients with PD experiencing pain [8,47,48,51e56].
This prevalence rate is much higher than that reported in the
general population (8%e25%) [47,51,52]. The treatment of muscu-
loskeletal pain in PD can vary depending on the cause. If the pain is
due primarily to parkinsonian rigidity, dopaminergic therapy,
physical therapy, and exercises are indicated [55].
Radicular-neuropathic painmanifests itself with pain, numbness
or weakness in the area of a nerve root as a consequence of nerve or
root compression [55]. Postural abnormalities and dystonia devel-
oping during the disease can lead to this type of pain through
discopathy [57]. The prevalence of radicular-neuropathic pain in
patients with PD experiencing pain ranges from 5% to 20%
[8,48,51e54,56].
Dystonic pain is represented by dystonic spasms which are
usually paroxysmal, spontaneous, or triggered by movement or
activity. They can be observed in the extremities, the face and the
pharyngeal muscles and are considered among the most painful
symptoms that a patient with PD may experience. The prevalence
of dystonia-related pain ranges from 8% to 47% [8,48,50e52,56] in
patients with PD experiencing pain. In contrast, this pain is not
present in healthy people. Symptoms can be more intense as early
morning manifestation of dopaminergic deﬁciency, and their
intensity decreases after dopaminergic medication [58]. In the old
days with high dose levodopa patients had ON dystonia as well.
Central pain is an insistent pain not restricted to nerve or
radicular territories that manifest as neuropathic sensory events
such as paresthesia or shooting pain. The patient usually describes
it as a bizarre and unexplained painful sensation predominately in
the more affected side and in the “OFF” state [47,59,60]. Central
pain can occur in different areas of the body including: the mouth,
rectum, vagina, abdomen, chest and testes [61e64]. The prevalence
of central pain in patients with PD is 10%e12% [8,53]. Central pain
can be mainly modiﬁed by dopaminergic medication as it seems to
be related to an abnormal function of the medial spinor-
eticulothalamic pathways [55]. In cases refractory to standard
treatment, conventional analgesics, opiates, tricyclics may be also
helpful [55].
The term akathitic discomfort (akathisia) is used to describe
subjective restlessness or the painful impulse to move continually.
It seems clear that this pain improves with levodopa treatment
[55].
Restless leg syndrome (RLS) is another source of pain in
patients with PD. It is deﬁned as a sensory-motor disturbance
that is prominent at night and improves with movement. It
includes intense and disagreeable sensations (paresthesia and
dysesthesia) of the extremities, more pronounced in the lower
extremities [65]. Some reports have indicated that the prevalence
of RLS in patients with PD ranges from 8% to 20% [66,67], which is
Table 1
Categorization and rate of pain in Parkinson’s disease.
Author Number subjects Pain evaluation Rate of pain Classiﬁcation of pain Rate of pain types Localization Factors affecting pain
Snider et al. [47] 101 PD patients
149 No PD patients
Medical record PD patients (40%)
No PD (8%)
Pain related to central nervous
system dysfunction
Burning
Tingling
Numbness
Pain
PD patients/No PD
11/0
22/3
21/1
29/3
Head or back, hand, foot Levodopa
Restless leg syndrome
Goetz et al. [48] 95 PD patients
(43 female, 52 male)
(43 pain, 52 no pain)
McGill Questionnarie 19 female (44%)
24 male (46%)
Muscular pain: muscle cramps,
tightness
Dystonic pain: painful dystonia
Radicular and neuritic pain: tingling
Diffuse generalized pain: discomfot of
akathisia
Joint pain: stiffness, pain with motion,
confused with joint
Talamic pain: Constant, boring,
ineffable and poorly lokalized pain
32 (74%)
12 (28%)
6 (14%)
1 (2%)
6 (14%)
0 (0%)
Neck, paraspinal muscles, calf
muscles
Feet
All body
Shoulders, hips, knees, ankles
Fluctuations
Levodopa
Disability
Worsening of
Parkinsonian
symptoms Posture
Increased resting tone
Scott et al. [49] 943 PD patients
(356 female, 587 male)
Questionnarie: SP-1/SP-2 One or more types
and areas of pain per
patient
Pain reported by patients (there is or
not)
Neck pain
Back pain
Muscle cramps
Female/Male
53.7%/44.9%
48.3%/40.7%
45.3%/41.4%
Neck
Low back
Calf muscle
Gender
Giuffrida et al. [54] 388 PD patients
(202 male, 186 female)
(269 pain, 119 no pain)
UPDRS (motor)
40.6  19.6
43.8  14.8
49.4  14.9
43.9  13.8
269 (67%)
One or more types and
areas of pain per
patient
Muscular pain: stiffness, cramps,
pseudo-cramps, pasms
Osteo-ligamentar rheumatologic pain:
articular, spinal, peri-articular
Neurogenic painful syndromes:
paresthesia, dysesthesia, burning
sensation
94%
51%
2%
e Motor ﬂuctuations
Tinazzi et al. [50] 117 PD patients
(50 male, 67 female)
(47 pain, 70 no pain)
VAS 47 (40%) Musculoskeletal pain: aching,
cramping, arthralgic, joint
Dystonic pain: pain associated with
dystonic movements
Central primary pain: burning, tingling
formication, bizarre quality
Akathitic discomfort
21%
8%
40%
4%
For all types of pain
Neck: 2.5%
Shoulder: 4%
Arm: 1%
Back: 9%
Leg or foot: 28%
Motor complications
Lee et al. [56] 123 PD patients
(64 female, 59 male)
Wisconsin Brief
Pain Inventory,
PACA and VAS
85% (according to
PACA)
Nociceptive pain: somatic and visseral
Neuropathic pain
Musculoskeletal pain
Dystonic pain
PD treatment-related pain
Other causes
94.7%
5.3%
62.6%
67%
0.8%
4.1%
Legs: 37.9%
Back: 16.5%
Feet: 11.2%
Arms: 10.5%
Neck: 9.1%
Hands: 6.7%
Not described
Negre-Pages et al. [51] 450 PD patients
(254 male, 196 female)
98 control
(53 male, 45 female)
VAS, DoPaMiP,
McGill Pain Questionnaire,
The Brief Pain Inventory
62% PD patients with
chronic pain
5.5% PD patients with
non-chronic pain
58.2% control subject
Dystonic pain
Neuropathic pain
Akathisia
Muscular pain: Deep aching, myalgia,
cramps, stiffness or articular discomfort
Non-PD pain
36%
7%
5%
2%
31%
Head: 8.7%
Back: 12.6%
Upper limbs: 21.4%
Lower limbs: 67%
Head: 11%
Back: 61%
Upper limbs: 14%
Lower limbs: 30%
Motor complications
Depressive symptoms
Age
PD duration
Dyskinesia
Severity of PD
Levadopa
Defazio et al. [52] 402 PD patients
(148 female, 254 male)
317 matched controls
(138 female, 179 male)
VAS PD Patients (70%)
Healthy (63%)
Dystonic pain
Muscular pain: cramping, spams, joint
pain, pain with motion
Peripheral neuropathic: pain in the
territory of a root or nerve
Central neuropathic pain: burning,
tingling, formication, or bizarre quality
6.7%
25.4%
4.7%
4.5%
Neck or shoulder: 6.2%
Arm: 11%
Back: 15.7%
Leg or foot: 19.9%
Depression
Medical conditions
Age
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(1%) [66].
In conclusion, the prevalence of all types of pain experienced
by individuals with PD is reported to be over 80% (Table 1);
however, discrepancies can be observed among the studies due to
different methodologies. Since pain and sensory symptoms in PD
represent a broad spectrum, a multidisciplinary approach to pain
management is recommended. Nevertheless, it has been found
that that 50% of patients with PD-related pain did not receive
treatment [8].3.3. Pain assessment in Parkinson’s disease (PD)
Pain thresholds have been evaluated with instruments such as
the visual analog scale or the McGill Pain Questionnaire in indi-
viduals with PD. Additionally, quantitative sensory testing
including thermal, electrical and mechanical pain thresholds have
been also assessed in patients with PD [15,20,45,46,59,68e72]
(Table 2). The results revealed several discrepancies including
patient’s proﬁle, pain threshold assessment, part of the body
examined, outcomes included, the assessment during ONeOFF
periods, and the use of levodopa. As a result, while some studies
had reported lower pain thresholds in individuals with PD
[45,46,69,72]; others report no differences [59,68,73], whereas one
study revealed higher thresholds [74]. Therefore, there is no
consensus on differences in pain thresholds between patients with
PD and controls due to the controversial nature of current ﬁndings
resulting from differences in the studies’ methodologies. In addi-
tion, similar conclusions are reported in relation to the effect of
administration of L-dopa in sensory thresholds since some studies
reported increased pain thresholds after the administration of L-
dopa, whereas others have reported no changes in pain thresholds
after L-dopa administration (Table 2).
Indeed, Dellapina et al. have demonstrated that treatment with
apomorphine did not also modify pain thresholds or pain-induced
cerebral activity in patients with PD when compared to placebo,
suggesting the possibility that monoamine systems other than
dopaminergic systems are involved in pain modulation [75]. The
lack of an effect of apomorphine to treat PD-related pain suggests
that dopamine agonists may not be as effective as L-dopa in the
treatment of pain [75]. Therefore, future studies are required to
further determine the role of dopamine agonist drugs in the
management of pain in PD.3.4. Factors potentially affecting pain in Parkinson’s disease (PD)
The presence of pain in PD is usually dependent of motor
problems e.g., rigidity, tremor, akinesia, or postural abnormalities.
In this section, we explore possible factor inﬂuencing the presence
of pain in PD.
3.4.1. Age
If we consider the mean age of this patient population, an
increase in the prevalence of musculoskeletal pain with joint
problems and degenerative changes elsewhere in the body would
seem to be expected. However, evidence surrounding this is
controversial. In the study by Goetz et al. patients with pain were
younger than those without pain [48]. Defazio et al. reported that
dystonia-related pain was observed at earlier ages [52]. Nègre-
Pagès et al. also observed that PD-related painwas seen at an earlier
age than pain unrelated to PD [51]. Studies reporting the absence of
correlation between age and pain have also been published
[8,50,56]. It is important to note that age has not systematically
been considered in all studies and the correlation between the
Table 2
Pain assessment in Parkinson’s disease (PD).
Year Study design Assessment methods for pain threshold Body part evaluated Results
Djaldetti et al. [59] 2004 Group 1: 36 hemi-PD patients (13 female, 23 male, 62
years old, disease duration 5.3, H&Yahr 1e2.5, UPDRS
III: 22.5  14.8, 21 with pain e VAS score was
48.9  24.1)
Group 2: 15 patients with ﬂuctions (65 years, 12 female,
3 male, disease duration 10.6, UPDRS III: 27.8  17.2, 12
patients with pain - VAS score 55.7  21.43)
Control group: 28 age-matched controls (58.9  6.6
years; 16 women and 12 men)
Tactile thresholds by using von Frey
ﬁlaments
Warm sensation and heat pain thresholds
(HPT)
Evaluation: before taking their ﬁrst
daily medication for all group
Group 2: assessment in ON and OFF
period
Bilateral forearm Mechanical and warmth sensory thresholds
equal in groups
Heat pain thresholds:
PD patients HPT < control subject
PD patients with pain HPT < PD patients
without pain
More affected side HPT < less affected side
Brefel-Courbon et al. [20] 2005 Group: 9 PD patients without pain (6 male, 3 female, 65
years, disease duration 9.6, Hoehn and Yahr 2e2.5,
UPDRS II OFF: 25  9, on: 15  7)
Control group: 9 healthy controls (6 male, 3 female,
age: 59 years)
Cold pain threshold (CPT) right hand by
immersion in cold water (temperature:
from 20 C to 0 C, reduced to 3 C by
3 C)
Hand temperature was measured by
using skin thermometer in OFF and ON
periods
Right hand OFF: pain threshold in PD patients < controls
ON: pain threshold in PD patients ¼ controls
Levodopa response: pain threshold during OFF
period in
PD patients < pain threshold during ON period
Gerdelat mas et al. [45] 2007 Group: 13 PD patients without pain (4 female, 9 male,
age: 62 years, disease duration 7.3 years, UPDRS ON:
10.8  8.8, UPDRS OFF: 21.2  11.8)
Control group: 10 healthy controls (4 female, 6 male,
age: 58 years)
The nociceptive ﬂexion reﬂex (RIII reﬂex)
All subjects were evaluated in ON and
OFF condition
Right leg OFF: PD patients < healthy subjects
ON: PD patients ¼ healthy subjects
Levodopa response: pain threshold during OFF
period in
PD patients < pain threshold during ON period
Vela et al. [68] 2007 Group: 50 PD patients (34 male, 16 female, age: 66
years, disease duration 8.0/ 25 patients without
dyskinesia (UPDRS: 19.95  9.16, H&Y 2.28  0.68 and
25 patients with dyskinesia (UPDRS: 24.56  8.35, H&Y
1.88  0.50)
Control group: 25 controls (12 male and 13 female, 62
years)
Pressure pain threshold (PPT) was
evaluated during ON period
The dorsal side of the proximal
phalanx of the second ﬁnger
and brachioradialis muscle
PPT was similar for three groups all body part
Women had lower PPT than men
Lim et al. [46] 2008 Group stable responders: 12 PD patients (8 male, 4
female, age 68 years, duration 3  1 years, UPDRS III
OFF: 30  3, UPDRS III ON: 26  3)
Group ﬂuctuators: 15 PD patients (7 male, 8 female,
age 64 years, duration 3 1 years, UPDRS III OFF: 27 3,
UPDRS III ON: 21  3)
Group dyskinetics: 23 PD patients (13 male, 10 female,
age 63 years, duration 6 1 years, UPDRS III OFF: 31 3,
UPDRS III ON: 19  2)
Control group: 23 age and sex matched healthy
subjects
Cold pain threshold (CPT): ﬁrst right
hand and later left hand was immersed
in an ice-water bath (water
temperature 1.0e2.0 C) until subject
felt “faintly painful”
To determinate “cold pain tolerance” the
hand was kept immersed until it
became ‘‘intolerable’’ or 180 s had
elapsed
Pain thresholds were evaluated in ON
condition
Right and left hand CPT and tolerance (OFF) Healthy > PD patients
After levodopa administration dyskinetic
patients exhibited a large increase in CPT and
tolerance that was absent in stable responders
Nolano et al. [15] 2008 Group: 18 PD patients (9male, 9 female, age: 62.7 years,
H&Y: 2.6  1.1, UPDRS III 26.6  10.2)
Control group: 30 age- and sex-matched healthy
subjects (61 years old)
Tactile threshold: Semmes-Weinstein
monoﬁlaments
Mechanical pain perception: calibrated
monoﬁlament, with a bending force of
95 mN
Thermal thresholds (cold, warm, cold
pain and heat pain thresholds)
All pain threshold tests were performed
during ON condition.
The dorsum of the hand and
foot of the less affected side in
PD patients
Tactile threshold: PD patients> control subjects
Mechanical pain perception: PD
patients < control subjects
Thermal thresholds (cold, warm, cold pain and
heat pain):
PD patients > control subjects
Mylius et al. [69] 2009 Group: 15 PD patients (8 patients with pain (PDP), 7
without pain (PDN), 6 female and 9 male, 63 years,
duration 11.0  5.4 years, UPDRS III 28.3  9.4, H&Y
2.3  0.7)
Control group: 18 control subjects (11 female and 7
male, 67 years old)
The nociceptive ﬂexion reﬂex (NFR)
Electrical pain threshold (EPT)
Heat pain thresholds (HPT)
Left or right calf NFR: PD patients < control subjects/PDN ¼ PDP
patients
EPT: PD patients < controls PDN ¼ PDP patients
HPT: PD patients < control subjects/PDN ¼ PDP
patients
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A. Fil et al. / Parkinsonism and Related Disorders 19 (2013) 285e294292different kinds of pain with age has not been investigated in some
studies.
3.4.2. Gender
Current thinking tends to favor the absence of gender differ-
ences in relation to the presence or absence of pain [48,50e53];
however, Beiske et al. reported that female gender was a signiﬁcant
predictor of pain in PD [8]. Scott et al. also observed that male and
female patients do not complain of pain in the same locations, since
women reported higher prevalence of neck and low back pain than
men [49]. Vela et al. [68] found lower pressure pain thresholds in
women. A link between pressure pain thresholds and musculo-
skeletal pain has been described [76], leading to the suggestion that
mechanical sensitivity is higher in women.
3.4.3. Severity and duration of the disease
The effect of severity and duration of disease on pain is
controversial. Nègre-Pagès et al. observed a correlation between
PD-related pain and the severity and duration of disease [51].
Similarly, a longer duration of disease and greater motor compli-
cations in patients with PD with pain have been reported as
compared to pain-free patients [50,77]. Other studies have not
found this correlation [8,52,53].
3.4.4. Depression
Symptoms of depression can be observed in PD patients,
ranging in intensity from mild to severe [78]. Considering that
chronic pain is a risk factor in the development of depression in
the elderly [79,80] and the older age and complications of PD
patients, a link between depression and pain seems probable.
Depression has been generally evaluated in studies of pain. Goetz
et al. reported that pain intensity correlated with depression, and
that the latter is more severe in patients experiencing pain than
in those without pain, even though the incidence of depression
was the same in both groups of patients [81]. Starkstein et al.
observed that pain was more frequent in patients with major
depression as compared to those with milder depression [82].
Similarly, a link between pain and depression in PD has been
reported by Ehrt et al. [77] and McNamara et al. [1]; however,
others have not shown a correlation between pain and depres-
sion [50,53]. Current evidence suggests that depression is
a parameter to be considered in studies of pain in patients with
PD, considering the frequency of depression in PD and the fact
that it can modify the perception of pain and it can be also
properly treatable.
3.4.5. Systemic disease and pre-existing disturbances
Patients with pre-existing pain related to systemic diseases such
as diabetes, osteoporosis, rheumatic disease, and age-dependent,
e.g., joint or disc disease or postural problems, will continue to
experience these after diagnoses; however, new disease related
symptoms, such as rigidity, akinesia, muscular cramps, and postural
instability can worsen these difﬁculties. Beiske et al. reported that
some patients complained of pain before the diagnosis of PD [8].
The results reported by Defazio et al. showed that joint pain and
peripheral neuropathic pain is seen in controls matched for age
with PD patients [52]. These studies support the theory that some
pain seen in patients with PD is related to age rather than the
disease itself.
The pain experienced by the patients prior to PD diagnosis could
be one reason for the controversial character of the ﬁndings
regarding the incidence of pain in PD. Several studies had generally
evaluated the presence of pain in a cross-sectional design, without
indicating if the complaints started before or after the diagnosis of
PD. On the other hand, such pain could also be related to the
A. Fil et al. / Parkinsonism and Related Disorders 19 (2013) 285e294 293disease, but appearing much earlier than the diagnosis [83].
Controlled studies in large patient populations deﬁning the time at
which the pain started and investigating it in detail according to its
different types are more than needed.
3.5. Pain and quality of life
Pain clearly affects the quality of life (Quol) of PD patients. A
link between pain, sleep problems and depression has been
described [81,84]. The interactions among these conditions
increase and complicate the problem by creating a vicious circle.
Some studies report that pain and other related conditions
negatively impact Quol in PD patients [85,86]. Barone et al. found
that non-motor disturbances negatively inﬂuence Quol and that
leg pain occupies third place in order of importance [87]. Politis
et al. examined the impact of PD from a patient’s perspective [88].
They classiﬁed patients into two groups according to the duration
of disease: early (<6 years) and late (>6 years), and asked them to
determine their problems in order of importance. Pain was one of
the most frequent non-motor problems in both groups. The early
PD patient group complained of musculo-cutaneous pain ﬁrst and
visceral pain second, whereas the late PD group listed musculo-
cutaneous pain in ﬁrst place, but dyskinetic and dystonia-related
pain second [88].
4. Conclusions
Pain in PD is likely related to pathologic changes in the
anatomical structures involved in nociceptive pain mechanisms.
Most studies on pain mechanism in PD have been conducted in
animals. Pain, one of the most frequent non-motor symptoms
affecting PD patients has complicated mechanism and is inﬂuenced
by several factors, e.g., age, gender, depression, severity, or duration
of the disease. Further, there are many methodological differences
among the studies aimed at classifying pain and characterizing its
subtypes. The fact that the patient population includes mostly the
aged increases the number of factors involved. There are also
problems with the studies investigating pain thresholds and
perception, as different studies follow different protocols and
consequently have different outcomes. There is a need for multi-
center studies with a large number of patients and controls, in
which patients should be evaluated in different dimensions for
measurable endpoints to acquire deﬁnitive data and open new
directions for treatment, of the pain so often present in patients
with PD.
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